Exosomes Derived from Bone Marrow Mesenchymal Stem Cells as Treatment for Severe COVID-19

• Published in: Stem cells and development Vol. 29; no. 12; p. 747
• Main Authors: Sengupta, Vikram, Sengupta, Sascha, Lazo, Angel, Woods, Peter, Nolan, Anna, Bremer, Nicholas
• Format: Journal Article
• Language: English
• Published: United States 15.06.2020
• Subjects: Adult; Aged; Aged, 80 and over; Betacoronavirus - pathogenicity; Bone Marrow Cells - cytology; Cell-Derived Microparticles - transplantation; Cohort Studies; Coronavirus Infections - mortality; Coronavirus Infections - therapy; COVID-19; Critical Illness - mortality; Critical Illness - therapy; Exosomes - transplantation; Female; Humans; Male; Mesenchymal Stem Cell Transplantation - adverse effects; Mesenchymal Stem Cell Transplantation - methods; Mesenchymal Stem Cells - cytology; Mesenchymal Stem Cells - ultrastructure; Middle Aged; Pandemics; Pneumonia, Viral - mortality; Pneumonia, Viral - therapy; SARS-CoV-2; Severity of Illness Index; Treatment Outcome; COVID-19; SARS-CoV-2; MSC; exosome; ARDS; bone marrow

This prospective nonrandomized open-label cohort study addresses the safety and efficacy of exosomes (ExoFlo™) derived from allogeneic bone marrow mesenchymal stem cells as treatment for severe COVID-19. During April 2020, ExoFlo was provided to 24 SARS-CoV-2 polymerase chain reaction-positive patie...